[Analysis of the prevalence of HIV resistant strains to antiretroviral drug in Privolzhsky Federal District].
Prevalence of the primary drug resistance mutations and resistance developed in patients receiving highly active antiretroviral therapies in the HIV-infected persons in the Privolzhsky federal district was studied. It was demonstrated that among the ART-naive HIV-positive patients there were no mutations leading to the development of resistance. A high level of the resistance to lamivudin, nevirapin, efavirenz was revealed among the persons receiving the antiretroviral therapy. As a whole, the frequency of mutations of resistance to nucleoside reverse transcriptase inhibitors (23.8%) and nonnucleoside reverse transcriptase inhibitors (26.9%) was much higher than to protease inhibitors (1.2%).
N N
NN
Zaĭtseva
O V
OV
Parfenova
E I
EI
Efimov
D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines / Q000627:therapeutic use*; D003521:Cyclopropanes; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics; D006678:HIV / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D059645:Mutation Rate; D019829:Nevirapine / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012426:Russia
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D054303:HIV Reverse Transcriptase; D016333:HIV Protease; C098320:efavirenz